Governance

Shareholders  Board of Directors 

Shareholders

Symbiotics SA, the mother entity, is owned by over 39 shareholders, mostly private individuals, all motivated by the mission and vision of the company. This relatively wide equity base is consistent with the founders' objective of avoiding concentration in the shareholding structure. It ensures independence of the company, diffusing responsibilities, strengthening the governance structure of the firm as it grows and institutionalizes. Most importantly, it creates positive synergies between a motivated group of diverse investors and professionals around a common mission. The company also follows strict good corporate governance principles, including the separation of roles between the board and management, and offers all staff the possibility to participate in the equity.

Board of Directors

Prof. Francis Waldvogel, Chairman

Prof. Francis Waldvogel, Chairman

Prof. Waldvogel is the Chairman of the Novartis Venture Fund. He is the former president of the council of the Swiss Federal Institutes of Technology and the former chairman of the advisory board of the Swiss Science and Innovation Forum.
Jeanne Barras Zwahlen, Vice-Chairwoman

Jeanne Barras Zwahlen, Vice-Chairwoman

Ms. Barras worked for many years as a senior economist at Credit Suisse Private Banking, notably representing the bank in the launch and administration of a microfinance investment fund (responsAbility).
Dominique Rochat, Secretary

Dominique Rochat, Secretary

Mr Rochat is attorney-at-law and partner of Lenz & Staehelin, one of the largest law firms in Switzerland.
Jean-Claude Marchand

Jean-Claude Marchand

Mr Marchand's more recent positions include Chief Operating Officer of Edipresse Group, Executive Member of the Board of Reuters and Chief Executive Officer of Reuters Information.
Ivan Pictet

Ivan Pictet

Mr. Pictet has spent almost his entire career with the bank Pictet & Cie, from which he retired as Senior Partner. He is currently President of the Fondation Pictet pour le développement and President of the Fondation pour Genève.
Philippe Sarasin

Philippe Sarasin

Mr. Sarasin's latest positions include partner of the private bank Lombard Odier Darier Hentsch & Cie and chair of the Association for Investment Management and Research (AIMR, now CFA Institute).
Michel Guillet

Michel Guillet

Mr. Guillet has held top management and administrative positions in the industrial and health sectors and in private equity. He is currently President of Adenia Partners (formerly I&P Management) an Africa-focused private equity firm.
In this section


Our business units
 

Legal Disclaimer: The collective investment schemes (the “Investment Products”) referred to on the following pages have not been approved for public distribution in or from Switzerland by the Swiss Financial Market Supervisory Authority (FINMA) pursuant to the Swiss Collective Investment Schemes Act of 23 June 2006 (the "CISA") and its implementing regulations. Accordingly, units of such Investment Products and information, documents or material pertaining to these Investment Products on the following pages may only be distributed in or from Switzerland to qualified investors (as such term is defined in the CISA and its implementing regulations). The information, documents and material pertaining to these Investment Products on the following pages are strictly confidential and do not constitute an offer to any other person or entity than Swiss qualified investors and may only be used by those qualified investors who have accessed them. They may not be copied, used by, distributed or made available to any other person.

Similarly the information on the following pages is only intended to be viewed by persons who fall outside the scope of any law that seeks to regulate financial promotions in the country of your residence or in the country in which the content of this website is being viewed.

If you are uncertain about your position under the laws of the country in which the content of this website is being viewed then you should seek clarification by obtaining legal advice from a lawyer practicing in the country of your residence or in the country in which the content of this website is being viewed before accessing this website.

The information, documents and material contained in the following pages are not warranted to be accurate, complete, or timely. More specifically, Symbiotics SA may not be held responsible for and does not take any position with respect to the accuracy and completeness of information in the following pages.

Agree    Disagree